Home/Pipeline/Roadmap™ Analysis

Roadmap™ Analysis

AI-assisted CCTA reading

CommercialActive (FDA Cleared 2022)N/A

Key Facts

Indication
AI-assisted CCTA reading
Phase
Commercial
Status
Active (FDA Cleared 2022)
Company

About HeartFlow

HeartFlow's mission is to transform coronary artery disease from a leading cause of death into a proactively managed chronic condition. The company has achieved remarkable commercial success, with its technology deployed in over 1,800 institutions, used on 600,000+ patients, and secured near-universal U.S. insurance reimbursement. Its strategy centers on expanding its AI-powered platform from a diagnostic tool into a comprehensive, longitudinal management system for CAD, leveraging a vast and growing clinical evidence base.

View full company profile